We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Intelligent Ultrasound Group Plc | LSE:MED | London | Ordinary Share | GB00BN791Q39 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.50 | 14.00 | 15.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMED
Medaphor Group PLC
07 February 2018
MedaPhor Group plc
("MedaPhor" or the "Group" or the "Company")
Investor presentation
MedaPhor Group plc (AIM: MED), the intelligent ultrasound software and simulation company, announces that it will be presenting at the Shares and AJ Bell Spotlight Evening in London on Tuesday 13 February 2018.
The Shares and AJ Bell Investor evening provides an opportunity for Directors to make a presentation and talk about their company business plans for 2018 direct to existing and potential investors.
The event will commence at 6pm at Novotel Tower Bridge, London, EC3N 2NR. At the event CEO Stuart Gall will deliver a presentation detailing the Company's strategy following the recent acquisition of Intelligent Ultrasound Limited, along with an overview of the Company, where it is currently positioned and their plans for the future.
If you are interested in attending the event and would like information on how to register please contact Walbrook PR at medaphor@walbrookpr.com
The presentation will contain no new material information and is available on the Company's website: http://investors.medaphor.com/
Enquiries:
MedaPhor Group plc www.medaphor.com Stuart Gall, CEO Tel: +44 (0)29 2075 Nicholas Sleep, CTO 6534 Cenkos Securities Tel: +44 (0)20 7397 8900 Camilla Hume/Bobbie Hilliam (Nominated Advisor) Michael Johnson / Julian Morse (Corporate Broking) Walbrook PR Tel: +44 (0)20 7933 8780 or medaphor@walbrookpr.com Paul McManus / Anna Mob: +44 (0)7980 541 893 / Mob: Dunphy +44 (0)7876 741 001
About MedaPhor (www.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops advanced hi-fidelity haptic and manikin based training simulators, clinical image analysis software tools, augmented reality based needle guidance software and artificial intelligence based automated scanning software for all medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US, MedaPhor is split into two divisions:
Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer(TM) OBGYN and General Medical simulator training platform, the HeartWorks(TM) echocardiography simulator platform and the BodyWorks Eve(TM) Point-of-Care simulator platform (launching January 2018). Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.
Intelligent Ultrasound
Focuses on developing augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. ScanNav(TM) uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of obstetric scanning. NeedleGuide(TM) aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXAKELAPEFF
(END) Dow Jones Newswires
February 07, 2018 02:00 ET (07:00 GMT)
1 Year Intelligent Ultrasound Chart |
1 Month Intelligent Ultrasound Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions